Biogen (NASDAQ:BIIB) Stock Price Target Raised at Barclays

Biogen (NASDAQ:BIIB) had its price target increased by Barclays from $200.00 to $230.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target suggests a potential downside of 8.02% from the company’s previous close.

Several other research firms have also recently weighed in on BIIB. Citigroup increased their price objective on shares of Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. upgraded shares of Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $210.00 to $300.00 in a report on Monday, October 12th. Bank of America upped their price target on shares of Biogen from $219.00 to $244.00 and gave the company a “neutral” rating in a research report on Thursday, October 22nd. Seaport Research Partners raised shares of Biogen to an “outperform” rating in a research report on Monday, October 12th. Finally, TD Cowen increased their price target on Biogen from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $242.96.

Biogen Trading Down 1.1%

Shares of BIIB stock traded down $2.67 on Wednesday, hitting $250.06. The company had a trading volume of 561,351 shares, compared to its average volume of 1,206,866. The stock’s 50-day moving average is $225.10 and its two-hundred day moving average is $200.10. Biogen has a twelve month low of $138.00 and a twelve month high of $258.78.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.81 EPS. On average, equities research analysts forecast that Biogen will post 12.29 earnings per share for the current year.

Institutional Trading of Biogen

Several large investors have recently modified their holdings of BIIB. BlackRock Inc. purchased a new stake in shares of Biogen during the 2nd quarter valued at approximately $3,453,878,000. Orbimed Advisors LLC bought a new position in Biogen in the 1st quarter worth approximately $11,293,000. Tidal Investments LLC grew its stake in Biogen by 9.0% in the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock valued at $13,794,000 after buying an additional 5,256 shares in the last quarter. Saudi Central Bank grew its stake in Biogen by 89.7% in the 2nd quarter. Saudi Central Bank now owns 10,273 shares of the biotechnology company’s stock valued at $2,220,000 after buying an additional 4,858 shares in the last quarter. Finally, Nippon Life Global Investors Americas Inc. purchased a new position in Biogen in the 2nd quarter valued at approximately $29,648,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted earnings of $2.62 per share, exceeding the Zacks consensus estimate of $2.06 and the broader consensus cited by MarketBeat of $1.99. Revenue reached $2.804 billion, above expectations of roughly $2.63 billion and up 11% year over year. Biogen Inc. Tops Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth Portfolio revenue rose 49% to $1.26 billion, benefiting from the first full quarter of contributions from acquired Apellis products. Total product revenue increased 13%, while rare-disease revenue grew 27% to $676 million, supporting the diversification strategy beyond multiple sclerosis treatments. Biogen Q3 Revenue Rises 11% as GAAP Loss Widens
• Positive Sentiment: Management raised the lower end of its 2026 reported non-GAAP diluted EPS outlook, now guiding to $12.20–$13.00. Piper Sandler also maintained its Buy rating, reinforcing bullish sentiment around Biogen’s growth products and acquisitions. Piper Sandler Maintains Buy Rating
• Neutral Sentiment: Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, versus year-ago GAAP earnings of $466.5 million, primarily reflecting $284 million of acquired in-process research and development, upfront and milestone expenses tied largely to the RayThera acquisition. These are significant near-term charges but may support future growth.
• Negative Sentiment: GAAP earnings declined sharply from $3.17 to a loss of $0.14 per share, and the stock’s strong recent run has raised concerns that much of the expected improvement is already reflected in its valuation. Biogen also ended the quarter with approximately $7.7 billion of debt, a consideration as acquisition spending continues.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.